{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:44:43Z","timestamp":1790203483165,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,4,1]]},"abstract":"<jats:p> Purpose: Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic leukemia (CLL). Previously, combinations of fludarabine and chlorambucil were abandoned because of increased toxicity from overlapping myelosuppression and immunosuppression. Of the purine analogs active in CLL, pentostatin may be least myelosuppressive. We hypothesized that combining pentostatin with cyclophosphamide would have less myelotoxicity than combinations using other purine analogs. <\/jats:p><jats:p> Patients and Methods: We studied 23 patients with previously treated CLL. All patients received pentostatin 4 mg\/m<jats:sup>2<\/jats:sup>. Seventeen patients received cyclophosphamide 600 mg\/m<jats:sup>2<\/jats:sup>, and six patients received cyclophosphamide 900 mg\/m<jats:sup>2<\/jats:sup>. Both drugs were administered on day 1 of each cycle, and cycles were repeated every 3 weeks for six treatments. Filgrastim, sulfamethoxazole\/trimethoprim, and acyclovir were administered prophylactically. The median number of prior treatment regimens was three (range, one to five) with 13 patients (57%) refractory to prior fludarabine therapy. <\/jats:p><jats:p> Results: The cyclophosphamide 900 mg\/m<jats:sup>2<\/jats:sup> dose level was associated with moderate to severe nausea, and we chose cyclophosphamide 600 mg\/m<jats:sup>2<\/jats:sup> as the dose for further study. There were 17 responses (74%; 95% confidence interval, 63% to 85%), including four complete responses. The response rate was 77% in fludarabine-refractory patients. Myelosuppression was acceptable with grade 3\/4 neutropenia and thrombocytopenia, seen in 35% and 30% of patients, respectively. The relative sparing of thrombopoiesis can be seen in that only one patient (5%) with an initial platelet count of more than 20,000 required platelet transfusions while receiving therapy. <\/jats:p><jats:p> Conclusion: Pentostatin 4 mg\/m<jats:sup>2<\/jats:sup> with cyclophosphamide 600 mg\/m<jats:sup>2<\/jats:sup> is safe and effective in previously treated patients with CLL. On the basis of these results, we are currently studying pentostatin, cyclophosphamide, and rituximab (PCR) therapy in patients with CLL. <\/jats:p>","DOI":"10.1200\/jco.2003.08.100","type":"journal-article","created":{"date-parts":[[2003,3,27]],"date-time":"2003-03-27T19:03:23Z","timestamp":1048791803000},"page":"1278-1284","source":"Crossref","is-referenced-by-count":91,"title":["Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia"],"prefix":"10.1200","volume":"21","author":[{"given":"Mark A.","family":"Weiss","sequence":"first","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Maslak","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Aliff","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley R.","family":"Frankel","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Kossman","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Horgan","sequence":"additional","affiliation":[{"name":"From the Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Cornell University Medical College, New York, NY; and the Greenebaum Cancer Center, University of Maryland, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.8.1901.1901"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.2.307.307"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"R4","unstructured":"Grever MR, Kopecky KJ, Coltman CA, et al: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457,1988\u2013459,"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.19.19"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.4.679"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.570"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1985.3.9.1196"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.433"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.44"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2878.2878"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-6-466"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1695.1695"},{"key":"R14","unstructured":"Elias L, Stock-Novack D, Head DR, et al: A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 7:361,1993\u2013365,"},{"key":"R15","unstructured":"Weiss M, Spiess T, Berman E, et al: Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 8:1290,1994\u20131293,"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.71"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Weiss M, Glenn M, Maslak P, et al: Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 14:1557,2000\u20131582,","DOI":"10.1038\/sj.leu.2401892"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704023161401"},{"key":"R20","unstructured":"Grever MR, Chapman RA, Ratanandotharathorn V, Siease RB. An investigation of deoxycoformycin in advanced cutaneous T-cell lymphoma. Blood 66:215a,1986,  (suppl 1, abstr 744)"},{"key":"R21","unstructured":"Johnston JB, Verburg L, Shore T, et al: Combination therapy with nucleoside analogs and alkylating agents. Leukemia 8:S140,1994\u2013S143,  (suppl)"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.29.29"},{"key":"R25","unstructured":"Flinn IW, Kopecky KJ, Foucar MK, et al: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96:2981,2000\u20132986,"},{"key":"R26","unstructured":"Margolis J, Grever MR: Pentostatin (Nipent): A review of potential toxicity and its management. Semin Oncol 27:9,2000\u201314,  (suppl 5)"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Keating M, O\u2019Brien S, Lerner S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165,1988\u20131171,","DOI":"10.1182\/blood.V92.4.1165"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.0680"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.08.100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:36:06Z","timestamp":1653510966000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.08.100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,1]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,4,1]]}},"alternative-id":["10.1200\/JCO.2003.08.100"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.08.100","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,1]]}}}